Back

Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials

26 August 2023 (15:40 - 15:50)
Organised by: Logo
Congress Presentation Part of: Insights from recent HFpEF trials 1 Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Xiaowen Wang

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial
Doctor S. Chatur (Boston, US)
Abstract Slides Video
Presentation thumbnail
Dietary sodium intake and outcomes: a secondary analysis from SODIUM - HF
Professor C. Saldarriaga (Medellin, CO)
Abstract Slides Video
Presentation thumbnail
Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF
Professor B. Pitt (Ann Arbor, US)
Abstract Slides Video
Presentation thumbnail
Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction
Doctor M. Pabon (Boston, US)
Abstract Slides Video
Presentation thumbnail
Effects of empaglifozin on collagen biomarkers in patients with heart failure. Results from the EMPEROR trials
Doctor M. Sumin (Mainz, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Insights from recent HFpEF trials 1
Video

The Event

Event poster

ESC Congress 2023

26 August 2023 15:40 CET
You may be interested in
thumbnail
Congress Presentation
Clinical characteristics and long-term outcomes of patients with heart failure with supra-normal ejection fraction: data from LECRA-HF registry.
thumbnail
Congress Presentation
Heart failure: the year in heart failure in the European Journal of Heart Failure
thumbnail
Congress Presentation
Heart failure with supranormal ejection fraction as a new HF phenotype. Clinical profile and prognosis of patients with based on the Heart Failure Observational Study of the Polish Cardiac Society

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources